Condition: Cardiac Allograft Vasculopathy · Sponsor: Ottawa Heart Institute Research Corporation
Cardiac allograft vasculopathy (CAV) is a common complication affecting heart transplant patients. This condition causes narrowing of the heart arteries leading to graft dysfunction. Surveillance for CAV is vital; however an ideal approach has not been established. The goal of this study is to assess whether noninvasive positron emission tomography (PET) based surveillance is non-inferior to invasive coronary angiography (ICA) surveillance.
This description comes directly from the study's public registry record.
Sharon Chih · 613-696-7000 · schih@ottawaheart.ca
Heather Ross · heather.ross@uhn.ca
Always discuss trial participation with your own doctor first.
| University of Calgary | Calgary, Alberta, Canada | Not Yet Recruiting |
| Mazankowski Alberta Heart Institute | Edmonton, Alberta, Canada | Not Yet Recruiting |
| University of Ottawa Heart Institute | Ottawa, Ontario, Canada | Recruiting |
| Toronto-General Hospital - University Health Network | Toronto, Ontario, Canada | Not Yet Recruiting |
| Montreal Heart Institute | Montreal, Quebec, Canada | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06089486